










STUDY PROTOCOL

# Diagnostic accuracy of $^{18}\text{F}$ Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: protocol for an overview of reviews [version 1; peer review: 2 approved]

Andrew Dullea <sup>1,2</sup>, Lydia O'Sullivan <sup>2,3</sup>, Marie Carrigan <sup>2</sup>, Susan Ahern <sup>2</sup>, Maeve McGarry<sup>2</sup>, Kirsty O'Brien <sup>2</sup>, Patricia Harrington <sup>2</sup>, Kieran A. Walsh <sup>2,4</sup>, Susan M. Smith<sup>1</sup>, Máirín Ryan<sup>2,5</sup>

<sup>1</sup>Discipline of Public Health & Primary Care, School of Medicine, The University of Dublin Trinity College, Dublin, Leinster, Ireland

<sup>2</sup>Health Technology Assessment Directorate, Health Information and Quality Authority, Cork, Ireland

<sup>3</sup>Trials Methodology Research Network, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, County Galway, Ireland

<sup>4</sup>School of Pharmacy, University College Cork, Cork, County Cork, Ireland

<sup>5</sup>Department of Pharmacology and Therapeutics, The University of Dublin Trinity College, Dublin, Leinster, Ireland

**V1** First published: 20 Sep 2023, 6:57  
<https://doi.org/10.12688/hrbopenres.13801.1>

Latest published: 20 Sep 2023, 6:57  
<https://doi.org/10.12688/hrbopenres.13801.1>




## Abstract

**Background:** Correct staging and risk stratification is essential in ensuring prostate cancer patients are offered the most appropriate treatment. Interest has been growing in the use of radiotracers targeting prostate specific membrane antigen (PSMA), including the use of  $^{18}\text{F}$ -PSMA PET-CT, as part of the primary staging or restaging of prostate cancer. Preliminary scoping identified a number of relevant systematic reviews and meta-analyses; however, individually, these each appear to look at only part of the picture. An overview of reviews aims to systematically identify, appraise and synthesise multiple systematic reviews, related to a relevant research question or questions. We present a protocol for an overview of reviews, which aims to collate existing evidence syntheses exploring the diagnostic accuracy of  $^{18}\text{F}$ -PSMA in staging and restaging of prostate cancer. It also aims to highlight evidence gaps in prostate cancer staging or restaging.

**Methods:** This protocol is reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for systematic review protocols (PRISMA-P). The search strategy will be designed in consultation with a librarian. Searches will be performed

## Open Peer Review

Approval Status  

	1	2
<b>version 1</b> 20 Sep 2023	 <a href="#">view</a>	 <a href="#">view</a>
1. <b>Sean Ong</b>  ,	The University of Melbourne, Melbourne, Australia	
2. <b>Laura Evangelista</b> ,	University of Padua, Padua, Italy	

Any reports and responses or comments on the article can be found at the end of the article.

in Medline (EBSCO), Embase (Ovid), Google Scholar and the Cochrane Database for Systematic Reviews, supplemented by a targeted grey literature search, forward citation searching and searching reference lists of included reviews. No language or date restrictions will be applied to the eligibility criteria or the search strategy. Title & abstract and full text screening will be performed independently by two reviewers. Data will be extracted by one reviewer and checked in full by a second reviewer. Quality appraisal will be performed using the Risk of Bias in Systematic Reviews (ROBIS) tool independently by two reviewers, and results will be narratively synthesised.

**Conclusions:** This overview of reviews may be of interest to healthcare professionals, academics and health policy decision-makers.

**Registration:** [OSF](#) (September 7, 2023).

### Keywords

Systematic Review, overview of reviews, prostate cancer, justification, PSMA, PET-CT

**Corresponding author:** Andrew Dullea ([dulleaa@tcd.ie](mailto:dulleaa@tcd.ie))

**Author roles:** **Dullea A:** Conceptualization, Formal Analysis, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **O'Sullivan L:** Conceptualization, Methodology, Supervision, Writing – Review & Editing; **Carrigan M:** Methodology, Writing – Review & Editing; **Ahern S:** Methodology, Writing – Review & Editing; **McGarry M:** Methodology, Writing – Review & Editing; **O'Brien K:** Methodology, Writing – Review & Editing; **Harrington P:** Methodology, Writing – Review & Editing; **Walsh KA:** Methodology, Supervision, Writing – Review & Editing; **Smith SM:** Methodology, Supervision, Writing – Review & Editing; **Ryan M:** Methodology, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** Andrew Dullea received tuition fees from the Health Information and Quality Authority (HIQA). This work was conducted as part of the Structured Population health, Policy and Health-services Research Education (SPHeRE) Programme under Grant No. SPHeRE/2022/1.

**Copyright:** © 2023 Dullea A *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Dullea A, O'Sullivan L, Carrigan M *et al.* **Diagnostic accuracy of <sup>18</sup>F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: protocol for an overview of reviews [version 1; peer review: 2 approved]** HRB Open Research 2023, 6:57 <https://doi.org/10.12688/hrbopenres.13801.1>

**First published:** 20 Sep 2023, 6:57 <https://doi.org/10.12688/hrbopenres.13801.1>

## Introduction

Prostate cancer is the second most commonly diagnosed cancer and the fifth leading cause of cancer death among men worldwide<sup>1</sup>. In Ireland, there are, on average, 3,474 new cases of prostate cancer per 100,000 people each year accounting for, on average, 29.2% of all invasive cancers diagnosed<sup>2</sup>. The most appropriate treatment strategy for a given patient often depends on the stage of disease, and the risk factors such as prostate specific antigen (PSA) level and Gleason score<sup>3-5</sup>. Evidence-based treatment strategies have been developed, and guidelines offer recommendations for specific sub-populations according to stage and risk<sup>3,6</sup>. Accurate diagnosis, staging, and risk stratification are therefore essential in ensuring the optimal treatment strategies are offered and the best possible patient outcomes are achieved.

At present, prostate cancer may be detected by digital rectal examinations, PSA levels, and trans-rectal ultrasound (TRUS); histopathological confirmation is usually required to confirm a diagnosis as abnormal findings may be explained by other benign conditions<sup>5</sup>. However, histopathological confirmation is not always possible or appropriate especially in recurrent or metastatic disease, or populations such as older adults ( $\geq 85$  years) and those with poor performance status. Metastatic spread to lymph nodes and distant organs is usually detected with 'conventional imaging' modalities, including a combination of computed tomography (CT), bone scintigraphy, and magnetic resonance imaging (MRI)<sup>5</sup>. The **PRO**state MRI Imaging Study (PROMIS) trial demonstrated that using MRI to triage patients with prostate cancer may allow 27% to avoid primary biopsy and result in an additional 18% clinically significant cancers being detected<sup>7</sup>.

However, there are a number of persisting limitations with the current reference standard of conventional imaging in the diagnosis and staging of prostate cancer. Despite improvements in the diagnosis and staging of disease with the addition of MRI, the false negative rate for MRI is estimated to be about 6.5% and sensitivity for lymph node imaging remains between 40–73%<sup>8,9</sup>. Pooled data from a meta-analysis of patients imaged using MRI also showed a sensitivity of only 57%, 58% and 61% for extra-capsular extension, seminal vesicle involvement and overall stage T3 assessment, respectively<sup>10</sup>. Similarly, MRI has poor sensitivity in detecting bone metastases. While bone scintigraphy performs better it still has a low sensitivity of approximately 68% for bone metastases<sup>8</sup>. Hence, there has been a growing interest in radiotracers that may help improve the diagnosis and staging of prostate cancer.

A number of different prostate specific membrane antigen (PSMA)-targeted radiotracers are increasingly being applied in clinical practice in an attempt to improve diagnostic accuracy and the sensitivity and specificity of staging. A number of different manufacturers offer similar PSMA radiotracers that differ slightly in terms of the radioligand attached, the exact antigen, and their pharmacokinetic properties<sup>11</sup>. In Ireland, <sup>68</sup>Ga PSMA is used as an alternative to conventional imaging investigations, where available. Such technology takes

advantage of the fact that the PSMA protein is rarely expressed in normal prostate tissue, but is highly upregulated and over-expressed in prostate cancer cells and tumour vascular cells<sup>12</sup>. While some national and international guidelines have adopted and recommended the use of PSMA positron emission tomography (PET) in combination with CT (PET-CT), others have not or have offered weak (as opposed to strong) recommendations<sup>3,4,6,13</sup>. Most notably, the proPSMA trial found <sup>68</sup>Ga-PSMA PET-CT to be a suitable replacement for conventional imaging, providing superior accuracy to the combined findings of CT and bone scintigraphy<sup>14</sup>. One meta-analysis found <sup>68</sup>Ga-PSMA PET-CT to have a higher sensitivity and a comparable specificity for staging pre-operative lymph node metastases in intermediate- and high-risk prostate cancer compared with MRI<sup>15</sup>. On a per-patient-based analysis, the sensitivity and specificity of <sup>68</sup>Ga-PSMA PET-CT were 77% and 97%, respectively, after lymph node dissection at the time of prostatectomy. On a per-lesion based analysis, sensitivity and specificity were 75% and 99%, respectively<sup>16</sup>. Two retrospective studies also found that <sup>68</sup>Ga-PSMA PET-CT and PET-MRI demonstrated superiority to MRI alone in the staging of lymph nodes and other areas<sup>17,18</sup>. However, the comparison of whole body MRI and PSMA PET-CT in detecting bone metastases has led to inconclusive and conflicting results in two small cohorts<sup>15,19</sup>.

Radiolabelling PSMA-targeted agents with <sup>18</sup>F instead of <sup>68</sup>Ga may provide several advantages, including improved image resolution and a longer half-life, which may enable better transportation logistics and access to the radiopharmaceutical<sup>20-23</sup>. Research into <sup>18</sup>F-PSMA has accelerated over recent years, yet high quality randomised control trials are lacking. Preliminary scoping of this topic identified a number of relevant systematic reviews and meta-analyses, however individually these each appear to be limited in the scope of their assessment. While some focus on diagnosis, others focus on detection rate, per patient or per lesion sensitivity, and consider a different array of comparators or populations (*e.g.*, high-risk patients *versus* those with biochemical recurrence, that is, those with a rising PSA after definitive treatment with surgery or radiotherapy). Overviews of reviews use explicit and systematic methods to search for, identify and appraise multiple systematic reviews on related research questions in the same topic area for the purpose of extracting and analysing their results across important outcomes. Thus, the unit of searching, inclusion and data analysis is the systematic review. Overviews often address research questions that are broader in scope than those examined in individual systematic reviews.

We present a protocol for an overview of reviews that aims to collate existing evidence syntheses on a range of diagnostic accuracy measures exploring the use <sup>18</sup>F-PSMA PET-CT in prostate cancer, using a range of comparators, in distinctly different populations. This overview focuses on high-risk patients and those with biochemical recurrence as these cohorts are most at risk for metastatic disease. In Ireland, these patients currently undergo conventional imaging or where available, <sup>68</sup>Ga-PSMA PET-CT. <sup>18</sup>F-PSMA imaging is suggested

as a replacement for  $^{68}\text{Ga}$ -PSMA imaging. While individual systematic reviews may focus on one or more aspects of Tumour, Node, Metastasis (TNM) staging, this overview aims to provide a more comprehensive picture of the evidence for  $^{18}\text{F}$ -PSMA PET-CT in prostate cancer staging and restaging. It also aims to highlight where evidence gaps exist. This work will help inform the generic justification of this practice in Ireland, and is being carried out by the Health Information and Quality Authority (HIQA).

### Study aims and research questions

This protocol has been registered on the [Open Science Framework](#) (September 7, 2023) and developed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for systematic review protocols (PRISMA-P)<sup>24,25</sup>. The completed PRISMA-P checklist is available from the registration site. The inclusion and exclusion criteria will follow a Population, Intervention, Comparator and Outcome (PICO) approach.

### Search strategy

Electronic searches will be conducted in Medline (EBSCO), Embase (Ovid), Google Scholar and the Cochrane Database for Systematic Reviews, supplemented by a grey literature search. No language or date restrictions will be applied to the eligibility criteria or the search strategy. The full search strategy can be found on Zenodo as *Extended data*<sup>26</sup>.

A list of sites included in the grey literature search are given on Open Science Framework as *Extended data*<sup>24</sup>. Forward citation searching and searching reference lists of included reviews will be conducted to identify other possibly relevant reviews. European Public Assessment Reports (EPARs) for authorised forms of the radiotracer will also be reviewed with a particular focus on identifying possible adverse events not reported within the peer-reviewed literature<sup>27</sup>.

### Screening

Records will be managed in Endnote V20<sup>28</sup>. Following removal of duplicates, title and abstract screening and full-text screening will be completed independently by two reviewers per the eligibility criteria ([Table 1](#)) using Covidence software<sup>29</sup>. Outcomes may be analysed on a per-patient, per-lymph node, per-lesion, or per-segment basis and similarly outcomes may be analysed according to the effect of PSA levels, Gleason Score, International Society for Urological Pathology (ISUP) grade and other clinicopathological characteristics. No restrictions will be placed on these sub-analyses as they all pertain to TNM staging and the risk category of the population. Studies which only report detection rate, positivity rate or median injection activity will not be included as these variables are of limited value to this overview. No restrictions shall be placed on the method of image analysis – visual, semi-quantitative analysis, or full quantitative analysis using maximum standardised uptake value (SUV<sub>max</sub>). No restrictions will be placed on definitions of biochemical recurrence, which may vary depending on the definitive treatment initially offered (*i.e.*, radical prostatectomy *versus* definitive radiotherapy). Definitions of ‘high-risk’ vary between many organisations and institutions, however any definition will be

accepted for the purposes of this overview. No restrictions will be placed on the reference standard, however the ‘gold-standard’ will be considered pathological confirmation determined *via* prostatectomy, pelvic lymph node dissection or biopsy as appropriate to the population under consideration. As study populations in this area often contain both intermediate and high-risk patients, these results will be extracted and will be considered relative to the results from well-defined high-risk populations in other studies.

Disagreements between reviewers will be resolved by discussion or, if necessary, by involving a third reviewer.

### Data collection and analysis

#### Data extraction and management

A standardised, electronic data extraction tool will be developed and initially piloted by the reviewers on a minimum of four systematic reviews. The initially proposed data extraction tool is available from the registration site on Open Science Framework<sup>24</sup>. Data will be extracted by a single reviewer and checked by a second reviewer. Disagreements will be resolved by discussion; any major or systematic disagreements may lead to the involvement of a third reviewer.

In addition to the outcomes listed in [Table 1](#), reviewers will extract information on the number of participants, statistical heterogeneity, assessment of publication biases, exact radiopharmaceutical, reference standard, comparator, and the author, year, and study design of both the reviews and the primary studies they included. Study authors will be contacted for additional information if necessary. If information on sensitivity and specificity is not reported in the systematic reviews, these will be calculated, where possible, using the information on the number of true positives, false positives, true negatives and false negatives.

Data extracted from the primary studies included in the systematic reviews will be cross referenced for discrepant data. Where partial information on a given primary study is reported by more than one systematic review, the record for the primary study will be generated using the information provided across those overlapping systematic reviews.

#### Risk of bias assessment

Where reported, the risk of bias assessment of the primary studies included within systematic reviews will be collected by reviewers and presented in the final report. Risk of bias is expected to be generally assessed at the study level, rather than at the level of the outcome for these primary studies. Where systematic reviews contain the same primary study, yet conclude differing levels of bias, the higher of the two biases will be assumed. As part of the inclusion criteria, all reviews should have some form of risk of bias or quality assessment.

The Risk of Bias in Systematic Reviews (ROBIS) tool will be used to assess the risk of bias of the included systematic reviews<sup>30</sup>. At present, there are no formal guidelines to recommend ROBIS over other tools such as Assessing the methodology quality of systematic reviews (AMSTAR-2)<sup>31</sup>. Two reviewers will independently assess the risk of bias of all included systematic reviews.

**Table 1. Population, Intervention, Comparator, Outcome (PICO).**

Patient/Problem:	➤ Adults aged 18 years and older with high-risk prostate cancer undergoing primary staging or adults with biochemically recurrent/persistent prostate cancer undergoing restaging.
Intervention:	➤ <sup>18</sup> F-PSMA PET-CT used to stage prostate cancer
Comparison:	<ul style="list-style-type: none"> <li>➤ Reference standards <ul style="list-style-type: none"> <li>○ Histopathology</li> <li>○ Clinical follow up (as defined by the study)</li> </ul> </li> <li>➤ Comparators <ul style="list-style-type: none"> <li>○ Conventional imaging using bone scan, CT or MRI.</li> <li>○ <sup>68</sup>Ga-PSMA PET-CT</li> </ul> </li> </ul>
Outcomes:	<p>Any of the following as they relate to TNM staging for prostate cancer:</p> <ul style="list-style-type: none"> <li>➤ Sensitivity</li> <li>➤ Specificity</li> <li>➤ Accuracy</li> <li>➤ Negative Predictive Value (NPV)</li> <li>➤ Positive Predictive Value (PPV)</li> <li>➤ Positive Likelihood Ratios</li> <li>➤ Negative Likelihood Ratios</li> <li>➤ Radiation Dose</li> <li>➤ Adverse Events (e.g., hypersensitivity, headache, fatigue, dysgeusia, paraesthesia).</li> </ul>
Study Design:	<ul style="list-style-type: none"> <li>➤ Only systematic reviews and meta-analyses will be considered for inclusion within the overview of reviews. Cochrane defines a systematic review as one that attempts to collate all empirical evidence that fits pre-specified eligibility criteria in order to answer a specific research question<sup>31</sup>. It uses explicit, systematic methods that are selected with a view to minimising bias, thus providing more reliable findings from which conclusions can be drawn and decisions made<sup>32,33</sup>. According to the Cochrane definition, the key characteristics of a systematic review are: <ul style="list-style-type: none"> <li>○ a clearly stated set of objectives with pre-defined eligibility criteria for studies;</li> <li>○ an explicit, reproducible methodology;</li> <li>○ a systematic search that attempts to identify all studies that would meet the eligibility criteria;</li> <li>○ an assessment of the validity of the findings of the included studies, for example through the assessment of risk of bias; and</li> <li>○ a systematic presentation, and synthesis, of the characteristics and findings of the included studies.</li> </ul> </li> <li>➤ Additionally, reviews must have all of the following characteristics: <ul style="list-style-type: none"> <li>○ a systematic search of at least two databases.</li> <li>○ a suitable analysis or subgroup analysis of risk groups or risk factors that allows reviewers to determine the effects on patients with high-risk (or intermediate/high-risk) prostate cancer or those with biochemically recurrent prostate cancer.</li> <li>○ a quality assessment will also be accepted in lieu of an established risk of bias tool such as QUADAS-2.</li> </ul> </li> </ul>
Languages:	➤ No language restrictions shall be put in place.

**Key:** <sup>18</sup>F - Fluorine-18; <sup>68</sup>Ga - Gallium-68; CT - computed tomography; MRI - magnetic resonance imaging; NPV - negative predictive value; PET-CT - positron emission tomography/computed tomography; PPV - positive predictive value; PSMA - prostate specific membrane antigen; TNM - tumour, nodes, metastasis; QUADAS - Quality Assessment of Diagnostic Accuracy Studies

### Data synthesis and certainty of the evidence

Results will be narratively synthesised, as it is anticipated that any meta-analytical approach would be inappropriate due to clinical heterogeneity. The narrative synthesis will be guided by the Synthesis Without Meta-analysis (SWiM) reporting guidelines<sup>34</sup>. The study design and a summary of the baseline characteristics for all included studies will be presented, followed by the overview's outcome results, risk of bias of the primary studies and risk of bias of the systematic reviews. It

is anticipated that most reviews, while having conducted a risk of bias assessment, will not have ascertained the certainty of the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework<sup>35</sup>. In keeping with JBI guidance, reviewers will attempt to apply the principles of GRADE in the overview of reviews to ascertain the certainty of evidence<sup>36</sup>. A modified version GRADE algorithm for downgrading will be used to generate summary of findings tables<sup>37</sup>. This approach attempts

to map the quality appraisal and risk of bias data onto the GRADE domains as originally set out by Guyatt *et al.*<sup>38</sup> The main modifications include the use of ROBIS instead of AMSTAR-2, an explicit focus on clinical heterogeneity rather than just statistical heterogeneity, and changes to the arbitrary sample sizes that determine downgrading (these cut-offs instead will be determined by what the reviewers consider an adequate sample size to determine sensitivity/specificity in these populations).

The overlap of primary studies between systematic reviews will be handled in line with Cochrane guidance<sup>31</sup>. All reviews may be included if overlap is sufficiently small, however another method such as excluding the older, poorer quality, or less comprehensive reviews may be employed if overlap is significant. A citation matrix will be used to visualise the amount of overlap, and the level of overlap will be determined by calculating the corrected covered area (CCA)<sup>39</sup>. The CCA is a measure of overlap calculated by dividing the frequency of repeat occurrences of the index publication in other reviews by the product of index publications and reviews, reduced by the number of index publications. A CCA of 0–5 indicates slight overlap, 6–10 moderate overlap, 11–15 high overlap and >15 very high overlap<sup>40</sup>.

### Deviations from the protocol

Amendments to the protocol prior to and during the conduct of the review will be documented by tabulating version history and important changes in the protocol. Any such deviations will be described in the final report.

### Discussion

This protocol describes each of the steps that will be undertaken as part of this overview of reviews. The proposed overview aims to consolidate existing evidence syntheses that assess different aspects of prostate cancer staging and restaging using <sup>18</sup>F-PSMA PET-CT to provide a comprehensive overview of the existing evidence, the certainty of the evidence, and the gaps in the evidence at present. We anticipate that the evidence from this overview will be of interest to healthcare professionals, academics and other health policy decision-makers.

HIQA is the competent authority for medical exposures to ionising radiation in Ireland. Part of HIQA's remit is the justification of new practices before they are generally adopted

(also known as Level Two or 'generic justification'). Generic justification considers whether the benefits of a new practice outweigh the risks, at a population level. In accordance with HIQA's [methods for generic justification](#), the findings from this overview of reviews will inform HIQA's decision on whether the practice of <sup>18</sup>F-PSMA PET-CT should be generically justified<sup>41</sup>.

### Study status

In progress.

### Data availability

#### Underlying data

No data are associated with this article.

#### Extended data

Open Science Framework: Diagnostic Accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high- risk prostate cancer patients and patients with biochemical failure: Protocol for an Overview of Reviews. <https://doi.org/10.17605/OSF.IO/QMEZ5><sup>24</sup>

This project contains the following extended data:

- 18FPSMA\_GreyLiteratureSources\_OSF\_2023\_03.docx
- F18PSMA\_DataExtractionTool\_OSF\_Template\_2023\_03.xlsx

Zenodo: Search strategies for generic justification of 18F-PSMA PET/CT in the staging of primary prostate cancer and the restaging of recurrent and metastatic prostate cancer. <https://doi.org/10.5281/zenodo.8159118><sup>26</sup>

### Reporting guidelines

Repository: PRISMA-P checklist for 'Diagnostic Accuracy of <sup>18</sup>F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: protocol for an overview of reviews'. <https://doi.org/10.17605/OSF.IO/FPZXD><sup>24</sup>

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

## References

1. Sung H, Ferlay J, Siegel RL, *et al.*: **Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries**. *CA Cancer J Clin.* 2021; **71**(3): 209–49. [PubMed Abstract](#) | [Publisher Full Text](#)
2. National Cancer Registry Ireland (NCRI): **Cancer in Ireland 19994-2018 with estimates for 2018-2020**. Cork, Ireland.: 2020. [Reference Source](#)
3. National Cancer Control Programme (NCCP): **National Clinical Guideline – Diagnosis and staging of patients with prostate cancer Version 2.0**. 2022. [Reference Source](#)

4. European Society of Radiology (ESR): **Imaging guidelines in newly diagnosed prostate cancer**. 2023; [16/08/23]. [Reference Source](#)
5. Mottet N, Bellmunt J, Bolla M, *et al.*: **EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent**. *Eur Urol*. 2017; **71**(4): 618–629. [PubMed Abstract](#) | [Publisher Full Text](#)
6. National Comprehensive Cancer Network® (NCCN®). Prostate Cancer V.3.2022. 2022.
7. Ahmed HU, El-Shater Bosaily A, Brown LC, *et al.*: **Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study**. *Lancet*. 2017; **389**(10071): 815–22. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Eyrich NW, Tosoian JJ, Drobish J, *et al.*: **Do patients who undergo multiparametric MRI for prostate cancer benefit from additional staging imaging? Results from a statewide collaborative**. *Urol Oncol*. 2020; **38**(7): 636.e13–636.e19. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Harisinghani MG, Barentsz J, Hahn PF, *et al.*: **Noninvasive detection of clinically occult lymph-node metastases in prostate cancer**. *N Engl J Med*. 2003; **348**(25): 2491–9. [PubMed Abstract](#) | [Publisher Full Text](#)
10. de Rooij M, Hamoen EH, Witjes JA, *et al.*: **Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis**. *Eur Urol*. 2016; **70**(2): 233–45. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Dias AH, Jochumsen MR, Zacho HD, *et al.*: **Multiparametric dynamic whole-body PSMA PET/CT using [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]PSMA-1007**. *EJNMMI Res*. 2023; **13**(1): 31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Sheehan B, Guo C, Neeb A, *et al.*: **Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications**. *Eur Urol Focus*. 2022; **8**(5): 1157–68. [PubMed Abstract](#) | [Publisher Full Text](#)
13. Physicians TRCo: **Evidence-based indications or the use of PET-CT in the United Kingdom**. 2022.
14. Hofman MS, Lawrentschuk N, Francis RJ, *et al.*: **Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study**. *Lancet*. 2020; **395**(10231): 1208–1216. [PubMed Abstract](#) | [Publisher Full Text](#)
15. Van Damme J, Tombal B, Collette L, *et al.*: **Comparison of <sup>68</sup>Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer**. *Cancers (Basel)*. 2021; **13**(21): 5286. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Perera M, Papa N, Roberts M, *et al.*: **Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis**. *Eur Urol*. 2020; **77**(4): 403–417. [PubMed Abstract](#) | [Publisher Full Text](#)
17. Maurer T, Gschwend JE, Rauscher I, *et al.*: **Diagnostic Efficacy of <sup>68</sup>Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer**. *J Urol*. 2016; **195**(5): 1436–1443. [PubMed Abstract](#) | [Publisher Full Text](#)
18. Herlemann A, Wenter V, Kretschmer A, *et al.*: **<sup>68</sup>Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer**. *Eur Urol*. 2016; **70**(4): 553–557. [PubMed Abstract](#) | [Publisher Full Text](#)
19. Anttinen M, Ettala O, Malaspina S, *et al.*: **A Prospective Comparison of <sup>18</sup>F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE)**. *Eur Urol Oncol*. 2021; **4**(4): 635–644. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Sengupta S, Asha Krishnan M, Chattopadhyay S, *et al.*: **Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer**. *Cancer Rep (Hoboken)*. 2019; **2**(4): e1169. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Wester HJ, Schottelius M: **PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy**. *Semin Nucl Med*. 2019; **49**(4): 302–312. [PubMed Abstract](#) | [Publisher Full Text](#)
22. Czarniecki M, Mena E, Lindenberg L, *et al.*: **Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents**. *Transl Androl Urol*. 2018; **7**(5): 831–43. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Eiber M, Fendler WP, Rowe SP, *et al.*: **Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy**. *J Nucl Med*. 2017; **58**(Suppl 2): 675–76S. [PubMed Abstract](#) | [Publisher Full Text](#)
24. Dullea A, O'Sullivan L, Carrigan M, *et al.*: **Diagnostic Accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high- risk prostate cancer patients and patients with biochemical failure: Protocol for an Overview of Reviews**. Open Science Framework (Registration). [Dataset]. 2023.
25. Shamseer L, Moher D, Clarke M, *et al.*: **Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation**. *BMJ*. 2015; **349**: g7647. [PubMed Abstract](#) | [Publisher Full Text](#)
26. Carriga M: **Search strategies for generic justification of 18F-PSMA PET/CT in the staging of primary prostate cancer and the restaging of recurrent and metastatic prostate cancer**. Zenodo [Dataset]. 2023.
27. European Medicines Agency: **Assessment Report: Pylclari (piflufolastat (18F))**. Amsterdam: 2018. [Reference Source](#)
28. The EndNote Team: **EndNote 20 ed**. Philadelphia, PA: Clarivate; 2013. [Reference Source](#)
29. **Covidence systematic review software**. Veritas Health Innovation, Melbourne, Australia. [Reference Source](#)
30. Whiting P, Savović J, Higgins JP, *et al.*: **ROBIS: A new tool to assess risk of bias in systematic reviews was developed**. *J Clin Epidemiol*. 2016; **69**: 225–34. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Pollock M FR, Becker LA, Pieper D, *et al.*: **Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)**. Cochrane: 2022. [Reference Source](#)
32. Antman EM, Lau J, Kupelnick B, *et al.*: **A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction**. *JAMA*. 1992; **268**(2): 240–8. [PubMed Abstract](#) | [Publisher Full Text](#)
33. Oxman AD, Guyatt GH: **The science of reviewing research**. *Ann N Y Acad Sci*. 1993; **703**: 125–33; discussion 133–4. [PubMed Abstract](#) | [Publisher Full Text](#)
34. Campbell M, McKenzie JE, Sowden A, *et al.*: **Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline**. *BMJ*. 2020; **368**: 16890. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Guyatt G, Oxman AD, Akl EA, *et al.*: **GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables**. *J Clin Epidemiol*. 2011; **64**(4): 383–94. [PubMed Abstract](#) | [Publisher Full Text](#)
36. Aromataris E, Munn Z: **JBIManual for Evidence Synthesis**. 2020. [Publisher Full Text](#)
37. Pollock A, Farmer SE, Brady MC, *et al.*: **An algorithm was developed to assign GRADE levels of evidence to comparisons within systematic reviews**. *J Clin Epidemiol*. 2016; **70**: 106–10. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Guyatt GH, Oxman AD, Vist GE, *et al.*: **GRADE: an emerging consensus on rating quality of evidence and strength of recommendations**. *BMJ*. 2008; **336**(7650): 924–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Gates M, Gates A, Guitard S, *et al.*: **Guidance for overviews of reviews continues to accumulate, but important challenges remain: a scoping review**. *Syst Rev*. 2020; **9**(1): 254. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Pieper D, Antoine SL, Mathes T, *et al.*: **Systematic review finds overlapping reviews were not mentioned in every other overview**. *J Clin Epidemiol*. 2014; **67**(4): 368–75. [PubMed Abstract](#) | [Publisher Full Text](#)
41. Health Information & Quality Authority (HIQA): **Methods for Generic Justification of New Practices in Ionising Radiation**. 2022.

## Open Peer Review

Current Peer Review Status:  

---

### Version 1

Reviewer Report 15 May 2024

<https://doi.org/10.21956/hrbopenres.15100.r36217>

© 2024 Evangelista L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Laura Evangelista**

University of Padua, Padua, Italy

The present manuscript aimed to describe the study protocol for evaluating the role of 18F-PSMA in patients with prostate cancer, either in the staging and restaging setting.

It is clear and concise in the definition of the end-point and in the selection of the population. Also some statistical analysis were mentioned.

No additional comments from my side.

**Is the rationale for, and objectives of, the study clearly described?**

Yes

**Is the study design appropriate for the research question?**

Yes

**Are sufficient details of the methods provided to allow replication by others?**

Yes

**Are the datasets clearly presented in a useable and accessible format?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Nuclear Medicine, Oncology, prostate cancer, breast cancer

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 15 May 2024

<https://doi.org/10.21956/hrbopenres.15100.r37847>

© 2024 Ong S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Sean Ong** 

The University of Melbourne, Melbourne, Victoria, Australia

The authors present a protocol for a systematic review of reviews in regards to PSMA PET radiotracers and their outcomes. Their reasoning and methods are sound. They have registered their study and have followed PRIMSA guidelines. I have no further comments to add.

**Is the rationale for, and objectives of, the study clearly described?**

Yes

**Is the study design appropriate for the research question?**

Yes

**Are sufficient details of the methods provided to allow replication by others?**

Yes

**Are the datasets clearly presented in a useable and accessible format?**

Not applicable

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Urology

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---